Paper Details

  1. Home
  2. Paper Details

Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.

Author: , AcostaEdward P, BrittoPaula, CareyVincent J, CresseyTim R, FocaMarc, GrahamBobbie, HazraRohan, Jean-PhilippePatrick, KingJennifer, WizniaAndrew, YogevRam

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study evaluated the pharmacokinetic interactions between rilpivirine (RPV) and darunavir/ritonavir (DRV/r) once daily in adolescents and young adults.
Paper Details　
Original Abstract of the Article :
Rilpivirine (RPV), a recently developed, once daily human immunodeficiency virus non-nucleoside reverse transcriptase inhibitor, is not currently approved for pediatric patients, but is sometimes prescribed for adolescents with multiple treatment failures, for regimen simplification or to minimize t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27187753

データ提供：米国国立医学図書館（NLM）

Rilpivirine and Darunavir/Ritonavir: A Desert Oasis of Treatment Options

The field of [HIV treatment] is a constantly evolving landscape, with researchers tirelessly seeking new and improved therapies. This study, like a caravan searching for a safe route through the desert of [HIV], investigates the interaction between two commonly used [antiretroviral drugs], [rilpivirine (RPV)] and [darunavir/ritonavir (DRV/r)]. The authors, using a [pharmacokinetic (PK) study] design, examined the impact of [DRV/r] on the [PK of RPV] in [adolescents and young adults]. Their findings, like a refreshing oasis in the desert, reveal that [DRV/r administration does not significantly alter the PK of RPV], offering a valuable piece of information for clinicians prescribing these drugs to young patients.

A Desert Oasis of Treatment Options

The study's results, like a clear desert sky, provide a reassuring picture for clinicians prescribing [RPV and DRV/r] to young patients. The study's findings suggest that [these drugs can be safely combined without significant pharmacokinetic interactions], offering a greater degree of flexibility for treatment regimens. This is like finding a reliable source of water in the desert, ensuring a smooth and effective treatment journey for young patients living with HIV.

Navigating the Desert of HIV Treatment: A Guide for Young Patients

For young patients living with [HIV], this study provides valuable information regarding their treatment options. It highlights the potential for [RPV and DRV/r] to be safely combined, offering a greater degree of flexibility and potentially improved outcomes. It's like finding a safe haven in the desert of HIV treatment, offering a path towards a healthier and more fulfilling life.

Dr.Camel's Conclusion

This study, like a camel navigating the treacherous desert of [HIV treatment], sheds light on the interaction between two important [antiretroviral drugs]. The study's findings, like a shimmering mirage, offer valuable insights for clinicians and researchers, paving the way for more effective and personalized treatment strategies for young patients living with HIV.

Date :
  1. Date Completed 2017-06-13
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

27187753

DOI: Digital Object Identifier

NIHMS786069

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.